Ko-Chung Lin
business executiveMale0.0Global Dominance: 0.00%
Ko-Chung Lin, Ph.D., is the founder and CEO of PharmaEssentia, a global biopharmaceutical company. He has played a crucial role in the development and approval of BESREMi®, which has been recognized as an important therapeutic option for patients with Polycythemia Vera, emphasizing the impact of international collaboration in healthcare advancements.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Ko-Chung Lin, Ph.D., founder and CEO of PharmaEssentia, stated that the approval of BESREMi® is a testament to the power of strong international partnerships in advancing healthcare.
Pint Pharma Anuncia la Aprobación de BESREMi® (ropeginterferón alfa-2b) por parte de ANVISA para el Tratamiento de la Policitemia VeraEl Nacional·
Venezuela· 2025-03-21
Venezuela· 2025-03-21
